Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $71.1 million.

  • Ovid Therapeutics' Shares Outstanding (Diluted Average) rose 19.5% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 19.5%. This contributed to the annual value of $70.9 million for FY2024, which is 46.02% up from last year.
  • Ovid Therapeutics' Shares Outstanding (Diluted Average) amounted to $71.1 million in Q3 2025, which was up 19.5% from $71.1 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Shares Outstanding (Diluted Average) registered a high of $71.2 million during Q2 2024, and its lowest value of $66.6 million during Q1 2021.
  • For the 5-year period, Ovid Therapeutics' Shares Outstanding (Diluted Average) averaged around $70.1 million, with its median value being $70.5 million (2023).
  • As far as peak fluctuations go, Ovid Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 1645.25% in 2021, and later fell by 12.82% in 2025.
  • Over the past 5 years, Ovid Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $68.1 million in 2021, then grew by 3.46% to $70.4 million in 2022, then increased by 0.22% to $70.6 million in 2023, then increased by 0.46% to $70.9 million in 2024, then grew by 0.29% to $71.1 million in 2025.
  • Its last three reported values are $71.1 million in Q3 2025, $71.1 million for Q2 2025, and $71.0 million during Q1 2025.